Page 21234..1020..»

You are currently browsing the Nano Medicine category

Research Roundup: Researchers Test Experimental COVID-19 Antibodies Treatment On Patients – Patch.com

§ September 19th, 2020 § Filed under Nano Medicine Comments Off on Research Roundup: Researchers Test Experimental COVID-19 Antibodies Treatment On Patients – Patch.com

By Derek Chen September 14, 2020

Each week, The Daily's Science & Tech section produces a roundup of the most exciting and influential research happening on campus or otherwise related to Stanford. Here's our digest for the weeks of Aug 30 Sept 12.

Coronavirus antibodies treatment in phase II experimental trials

Stanford Medicine researchers are participating in a phase II multi-site clinical trial to test an antibody-drug designed to diminish early COVID-19 symptoms in patients with mild to moderate cases. Preliminary results are expected later this month.

"The goal is to see if we can get sick people better faster, reducing both the length of their illness and how long they are shedding the virus, and therefore help prevent others from getting sick," Department of Emergency Medicine Chair Andra Blomkalns told Stanford Medicine News. "I think this treatment shows great promise."

At Stanford Hospitals, the clinical site aims to enroll 20 to 40 patients who have tested positive for COVID-19. The experimental treatment involves using antibodies from patients who have recovered from COVID-19, then injecting these antibodies into COVID-19 positive patients.

"Our hope is to effect treatment early in the course of disease, before it has time to progress further and potentially damage organs," Blomkalns said.

Microorganism yeast cells reprogrammed to produce plant-based drugs

Yeast cellular machinery can be genetically reprogrammed to change these microscopic organisms into factories that convert sugar and amino acids into plant-based drugs, a study published on Sept. 2 in "Nature" reports.

"The drug shortages we're seeing around the COVID-19 crisis drive home why we need new and more reliable ways to source these plant-based medicines, which take months to years to grow and come from a few countries, where climate change, natural disasters and geopolitical issues can disrupt supplies," bioengineering professor Christina Smolke told Stanford News.

The findings suggest that by making genetic modifications to the organelles found in yeast cells, the team can manipulate cellular processes to manufacture the desired chemical drug. In this case, researchers wanted to produce tropane alkaloid molecules for medicinal uses.

"Plants are the world's best chemists," Smolke said. "We want to recapitulate their unique and useful chemistries in domesticated microbes to build complex molecules inspired by the natural world but tailored to better meet human needs."

Mosquito-borne disease likelihood increases as climate warms

In Sub-Saharan African, malaria rates are predicted to decrease, while other mosquito-borne diseases such as dengue fever, will increase significantly due to warming climates and urbanization, a study published on Sept. 9 in "Lancet Planetary Health" reports.

"Climate change is going to rearrange the landscape of infectious disease," biology assistant professor Erin Mordecai told Stanford News. "Chikungunya and dengue outbreaks like we've recently seen in East Africa are only becoming more likely across much of the continent. We need to be ready for this emerging threat."

The Aedes aegypti mosquito can transmit a wide variety of diseases, including Rift Valley Fever, yellow fever, Zika, chikungunya and dengue. The findings suggest that Aedes aegypti breeding grounds have expanded due to urbanization and warming climate. The mosquitos enjoy living in human-made water containers, like buckets or water storage tanks, and warm temperatures.

"It's vital to focus on controlling mosquitoes that spread diseases like dengue because there are no medical treatments for these diseases," pediatrics professor Desiree LaBeaud told Stanford News. "On top of that, a shift from malaria to dengue may overwhelm health systems because diseases introduced to new populations often lead to large outbreaks."

Contact Derek Chen at derekc8 'at' stanford.edu.

The Stanford Daily is the independent, student-run newspaper of Stanford University. Read more of their stories at StanfordDaily.com.

The rest is here:
Research Roundup: Researchers Test Experimental COVID-19 Antibodies Treatment On Patients - Patch.com

Read the Rest...

Scientists release first-ever high-powered microscopic images of COVID-19 – Republic World – Republic World

§ September 19th, 2020 § Filed under Nano Medicine Comments Off on Scientists release first-ever high-powered microscopic images of COVID-19 – Republic World – Republic World

On September 13, scientists at the University of North Carolina (UNC) Childrens Research Institute released the first-ever high-powered microscopic images of the SARS-CoV-2 infection in the lungs airways. A team of scientists, including Camille Ehre, captured the COVID-19 infection progressing on the lab-grown respiratory tract cells which demonstrates the intensity of the infection across lung tissues and how rapidly it could spread to others. Images depict a large number of coronavirus particles settled on the human respiratory surfaceswhich were first recorded as monochrome, then later re-colourized and published in the New England Journal of Medicine.

According to the scientists, the images released show the infectious form of SARS-CoV-2 as released by infected host cells onto respiratory surfaces. Scientists first injected the novel coronavirus into the laboratory bronchial epithelial cells of the human lungs and then examined the progress of the COVID-19 respiratory disease for almost 96 hours with a high-powered scanning electron microscopy. Later, the images of the coronavirus on the human respiratory surface were captured that also suggest the importance of the usage of masks, given the large amount of the virus burden observed in the lung airways.

Large viral load is a source for the spread of infection to multiple organsand determines the frequency of coronavirus transmission to others, scientists explained in the study published in the New England Journal of Medicine.

Read:Scientists Come Up With Atomic-level Resolution View Of Coronavirus'replication System

Read:Hong Kong Authorities To Unveil Additional COVID-19 Relief Measures After $37bn Package

The scientists from the University of North Carolina (UNC) suggest in the study that the large coronavirus burden on the respiratory surfaces could rapidly lead to the infection of multiple organs in a coronavirus positive individual. Therefore, to limit the amount of this virus load, that determines the intensity of the illness, the use of masks must be mandated. In the images, it can be seen that the hairy ciliated cells in the lungs are infected with strands of mucus attached to cilia tips. These hair-like structures transport mucus and trapped viruses from the surface of airway epithelial cells in the lungs.

The density of the coronavirus on the human airway epithelia can be seen in the images, which also depict the large number of virions produced and released per cellin the respiratory system.

Virion is an entire virus particle consisting of an outer protein shell (capsid) and an inner core of nucleic acid (either RNA or DNA), Scientists explained in the study.

Read:Chinese Virologist Claims COVID-19 Originated From Wuhan Lab, Offers Evidence

Read:Post-COVID-19 Care Gains Equal Importance With Daily Recoveries Exceeding 70,000 Mar

(Images Credit:New England Journal of Medicine.)

The rest is here:
Scientists release first-ever high-powered microscopic images of COVID-19 - Republic World - Republic World

Read the Rest...

COVID-19 In India: Easy To Say Vaccine Will Be Released By Next Month But Do You Even Know How Long It Takes To Make? – Inventiva

§ September 19th, 2020 § Filed under Nano Medicine Comments Off on COVID-19 In India: Easy To Say Vaccine Will Be Released By Next Month But Do You Even Know How Long It Takes To Make? – Inventiva

Any updates on antibodies are a quick head-turner given that economies have smashed and nations have halted while the Covid-19 pandemic keeps on seething. Presently, more than 1 crore individuals have been tainted worldwide in a half year since the main case was accounted for in Chinas Wuhan. The infection has no known treatment yet.

The Narendra Modi government more than blew some peoples minds Friday with reports that it was planning to have an immunization prepared in about a month and a half, the preliminary for which is yet to start.

Antibodies are confounded to create and ordinarily set aside extensive stretches of effort to screen for viability, wellbeing, and symptoms.

Furthermore, it is dishonest to uncover members in a preliminary straightforwardly to a microorganism, hence dragging out the length of perception. However, because of the outrageous dire requirement for a COVID immunization, numerous antibody preliminaries have taken the questionable choice to deliberately contaminate study members to show up at results quicker.

How about we see how long immunizations take to grow, how they are assisted, and what the various kinds of antibodies being created for COVID are.

How immunizations work

Immunizations are natural substances which, when infused into our bodies, launch our invulnerable reaction to deliver antibodies. They do as such via conveying a more vulnerable type of microorganisms or infection or any malady causing microbe.

The measurement of the microbes doesnt hurt our body however is conspicuous enough as an unfamiliar trespasser with the goal that the invulnerable framework begins battling it. Our invulnerable framework currently recalls the microbe it fended off, in this way remembering it at whatever point it or a comparative microorganism enters the body whenever. This outcomes in an inoculated individuals safe framework reacting quicker, guaranteeing the individual doesnt get the sickness.

Immunizations can be both prophylactic to forestall illness, and remedial to support a characteristic invulnerable reaction to a malady that has just tainted the body, similar to malignant growth.

Antibodies, all in all, ensure the populace and have been utilized to control plagues just as destroy ailments. The world has annihilated two up until now little pox in people and rinderpest in creatures.

Phases of antibody advancement

Immunizations and medications experience different phases of improvement, and with each stage, numerous antibody applicants get sifted through.

An exploratory phase of two to four years is the point at which the cycle regularly starts, where antigens are recognized and a potential guide for the antibody is drawn out. They at that point enter a pre-clinical stage or Phase 0 where microbial material is tried in vitro (in cell and tissue societies) just as on creatures to comprehend results that could be normal in people. This stage ordinarily endures one to two years.

Notwithstanding a pandemic like COVID, scientists are morally free to skirt these stages and straightforwardly dispatch into Phase I. This is the point at which the immunization is acquainted with people first. The goal is to build up the wellbeing of the immunization and comprehend the degree of invulnerable reaction. It ordinarily includes under 100 individuals and could last between a while to a year or two.

If security is set up, Phase II begins where 100 to 300 individuals are selected to test adequacy and comprehend symptoms. This goes on for around a few years.

Frequently, to assist testing, Phases I and II are joined.

Stage III preliminaries are the most critical. They keep going for around five to 10 years and select around 3,000 members for one immunization. The effective finish of Phase III is when genuine adequacy can be built up.

Once measurably critical viability is demonstrated, an immunization goes through an endorsement cycle (regularly two years), which additionally includes fabricating, scaling up, and drawing an inoculation drive plan, after which it is turned out or disseminated. When inoculation drives are in progress, Phase IV initiates, where long haul wellbeing and adequacy are contemplated.

The normal season of antibody improvement is somewhere in the range of 10 to 15 years in non-crisis circumstances.

Various types of antibodies

Antibody classifications are comprehensively ordered into two.

Live, constricted immunizations convey an amazingly debilitated microorganism that cant cause the ailment, for example, the measles or BCG (Bacillus CalmetteGurin) antibodies. Slaughtered or inert antibodies utilize either dead microorganisms or parts of a microbe. These antibodies are not as amazing as live ones and regularly require sponsor shots.

A murdered immunization can either convey the whole slaughtered microbe, for example, rabies or flu antibodies, or be a sub-unit immunization which doesnt contain a full cell yet rather contains portions of a microorganism, for example, sugars or proteins found on the outside of microscopic organisms or infection. Hepatitis B and Human papillomavirus (HPV) antibodies are sub-unit immunizations. Indeed, even some formative COVID immunizations, as Novovax utilizes the spike protein of the infection to assist antibodies with perceiving the protein later.

There are currently various types of hereditary immunizations utilizing more up to date advances, for example, DNA/RNA antibodies where the hereditary material of a microorganism is acquainted with our bodies. Various RNA immunizations are presently being tried for COVID.

There are additionally popular vector immunizations, where one infection conveys hereditary material of another into our bodies straightforwardly, for example, the Oxford antibody being produced for COVID, where the spike protein quality is embedded into a chimp adenovirus.

The worldwide extended timetable for a working COVID immunization to be created is at any rate nine to a year, with antibody makers and different specialists saying that it could take as long as two years.

No antibody has been grown effectively inside courses of events like COVID.

The quickest to be affirmed and authorized was the mumps antibody, which went from gathering viral examples to being authorized in four years. The Ebola antibody was additionally optimized as a worldwide reaction to the serious 2014 episode, although the infection had been around since the 1970s. After testing and advancement, the antibody was affirmed and authorized among November and December of 2019and is required to reveal this year.

From antiretrovirals to steroids, from focussing on ventilators to now searching for oxygen, a great deal has changed in the norm of care for Covid-19 in the course of recent months in India.

On Saturday, the Ministry of Health and Family Welfare gave overhauled treatment rules including dexamethasone, the economical and effectively accessible steroid, in treatment conventions.

The update, the fourth until date, comes almost fourteen days after the last one and after the consequences of recuperation preliminaries in the United Kingdom, utilizing dexamethasone, were made accessible on 18 June.

This is the way quickly the information about the infection has been evolving. By expansion, so have methodologies to oversee patients since the time the primary instance of novel SARS CoV2 infection was recognized at Wuhan in China in January.

This is a pandemic, so the circumstance is dynamic. What is the norm of care today may not be so 15 days from now, said Dr. Kedar Toraskar, chest doctor, Wockhardt Hospital, Mumbai, and an individual from the Covid-19 taskforce in Maharashtra. He, in any case, included that the information on the most recent three months has made the clinical network smarter about the ailment.

The reexamined rules too the one preceding it additionally incorporate remdesivir, gaining strength plasma treatment, and tocilizumab for moderate patients under investigational treatments, which have restricted accessible proof.

From the initial barely any weeks when it wasnt sure about how to deal with patients and what could be the conceivable movement of the illness and manifestations, there has been a considerable amount of progress.

Presently, the clinical club will before long have the option to discover if treatments still under scrutiny including remdesvir, favipiravir, undeveloped cells, plasma treatment and tocilizumab have any advantage or not, said Dr Rashid Gouri, a senior occupant at AIIMS, New Delhi, who treats Covid-19 patients.

READ Lockdown Impact: Amazon Vice President Resigns And A Few Companies Who Have Sacked Their Employees!

Most patients show gentle manifestations, get well at home

Perhaps the greatest change in the norm of care has been the way that most Covid-19 positive cases have gentle manifestations and neednt bother with hospitalization and can show signs of improvement either in-home seclusion or institutional detachment habitats.

As per the biggest investigation of Covid-19 patients done in China and distributed in the Chinese Journal of Epidemiology, 95 percent of patients experience the ill effects of mellow manifestations, while 15 percent need oxygen treatment and 4-5 percent need ventilation.

Those with mellow indications can be observed for oxygen immersion with heartbeat oximetry and temperature at the COVID Care focuses. Ifthe oxygen immersion dips under 80 percent, patients are prescribed to a higher focus.

The wellbeing services rules delivered in May likewise suggested that solitary the serious patients be moved to committed COVID clinics. It likewise permitted gentle and moderate patients to be released in 10 days without an affirmation test on the off chance that they had no manifestations for over three days. Prior patients required two negative RT PCR tests before release.

The current strategy bodes well as just the serious patients are involving the beds, specialists told.

Coronavirus contamination has two sections, one section where the infection reproduces and another part when there is an irritation that incorporates the cytokine part, said Dr. Om Srivastav, irresistible malady master from Jaslok Hospital, Mumbai.

He said the infection replication occurs in the initial 10 days and the effect on heart or lung occurs in the aggravation part of the disease after the 10 days.

Presently the treatment methodology has been developed to recognize which part of the contamination the patient is in and address that part more forcefully, said Srivastav. So the specialists endorse antivirals during the initial 10 days and calming drugs after the initial seven or 10 days.

READ YC-backed Statiq wants to bootstrap Indias EV charging network

No HCQ and Azithromycin, Tamiflu, Vitamin C

The rules in March just suggested Hydroxychloroquine (HCQ) and Azithromycin for extreme patients as no different antivirals were demonstrated to be successful.

While Azithromycin has been dropped from current rules, HCQ is as yet included.

Numerous ongoing examinations have demonstrated HCQ isnt viable in diminishing mortality or results in numerous preliminaries, including RECOVERY preliminaries. It has been dropped from the World Health Organizations progressing Solidarity preliminary to locate a powerful treatment for Covid-19 that included four medications.

The services momentum rules notice that since these enormous observational examinations had a few constraints, HCQ is suggested in the beginning phase of the illness after an electrocardiogram is performed.

Specialists, nonetheless, said that the utilization of HCQ in emergency clinics has nearly been halted now. In the wake of taking a gander at the consequences of the examinations, we have now quit giving HCQ for over two months currently, said Toraskar, who included that the mix of HCQ and Azithromycin is destructive and has additionally been halted.

Additionally the utilization of zinc, nutrient C tablets have halted just as that of oseltamivir, which worked for H1N1 disease, however, hasnt demonstrated success for Covid-19.

Next came the antiretroviral drug blend of lopinavir-ritonavir, which was likewise used to treat patients in Jaipur. After starting a guarantee, notwithstanding, the mix didnt show promising results in preliminaries and was dropped.

The part of antiretroviral drugs lopinavir and ritonavir may now go down with new trial medicines like remdesivir and favipiravir coming in, however, these enemies of HIV drugs have assumed a significant function up to this point, Dr. Gouri of AIIMS said.

Tenderfoots: Remdesivir and favipiravir

Presently the two antiviral medications that have much media consideration are remdesivir and favipiravir.

Favipiravir, an oral antiviral medication initially produced by Fuji Films and utilized for safe flu in 2014, has as of late been authorized to be sold in India at a cost of Rs 103 for every pill.

The medication, nonetheless, is definitely not an enchantment shot and can diminish the recuperation time yet should just be utilized for mellow patients. There are still no enormous preliminaries that have demonstrated its adequacy, said a few specialists.

The issue with the medication is likewise that the pill trouble is high. You need to take nine pills the primary day and four pills two times every day for 6-14 days, said Dr Toraskar.

Remdesivir, an intravenous antiviral medication has indicated great outcomes and was first suggested by the US top general wellbeing authority, the National Institute of Allergy and Infectious Diseases (NIAID), in April. The medication decreased the recuperation time yet didnt significantly affect mortality.

The medication is best utilized for moderate to extreme patients and is utilized in the emergency unit the initial 10 days of the disease, said Dr. Toraskar.

In India, remedesivir was just accessible under humane use and will before long be accessible for crisis limited use in emergency clinics after Cipla and Hetero got the permit for assembling and deal.

Remdesivir has indicated great outcomes on the 25 patients that we utilized the medications for in the ICU, said Dr Harsh Chafle, expert intensivist and chest doctor, Global Hospital, Mumbai.

Steroids have a job

Specialists were utilizing steroids in the serious consideration units however now have been approved by the UK RECOVERY preliminary, which has demonstrated that dexamethasone can lessen mortality for extreme patients and the individuals who require ventilation.

The investigation utilized 6 mg of dexamethasone for 10 days on decently sick patients and the individuals who need oxygen supplementation.

It is critical to realize that if you use it early or for gentle patients, it will be destructive, said Toraskar, who included that it ought to be utilized after the tenth day for patients who are tolerable to seriously sick and who require oxygen.

There is additionally a function for anticoagulants or blood-thinners since the Covid-19 has been known to cause irritation and clump development. These are suggested for moderate patients in the new rules.

READ A Washington ISP exposed the keys to the kingdom after leaving a server unsecured

Oxygenation and Pruning

Prior, the technique was to utilize a ventilator at an early stage yet now the methodology is to defer utilizing an obtrusive ventilator however much as could be expected, said Dr. Chafle. Obtrusive ventilation is the point at which a cylinder is embedded into the patients windpipe by a cycle called intubation.

Presently, specialists favor oxygenation through high stream nasal cannula (HFNC) and non-obtrusive ventilators.

Clarifying how HFNC functions, Chalfe stated,

Oxygen can be given in focal oxygen giving gadgets or chambers. HFNC gadgets give a similar oxygen all the more successfully by giving it with high weight and dampness.

Patients who were intubated have revealed higher mortality yet that is because those patients are more genuine, said Dr. Toraskar. The plan to defer intubation is to lessen the aggravation with steady oxygen and medications.

Read more here:
COVID-19 In India: Easy To Say Vaccine Will Be Released By Next Month But Do You Even Know How Long It Takes To Make? - Inventiva

Read the Rest...

Mercury Ore Market 2019 Industry by Type, by Application and by Region Forecast to 2023 – The Daily Chronicle

§ September 19th, 2020 § Filed under Nano Medicine Comments Off on Mercury Ore Market 2019 Industry by Type, by Application and by Region Forecast to 2023 – The Daily Chronicle

With having published myriads of reports, Mercury Ore Market Research imparts its stalwartness to clients existing all over the globe. Our dedicated team of experts deliver reports with accurate data extracted from trusted sources. We ride the wave of digitalization facilitate clients with the changing trends in various industries, regions and consumers. As customer satisfaction is our top priority, our analysts are available 24/7 to provide tailored business solutions to the clients.

In this new business intelligence report, Mercury Ore Market Research serves a platter of market forecast, structure, potential, and socioeconomic impacts associated with the global Mercury Ore market. With Porters Five Forces and DROT analyses, the research study incorporates a comprehensive evaluation of the positive and negative factors, as well as the opportunities regarding the Mercury Ore market.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.researchmoz.com/enquiry.php?type=S&repid=2633884&source=atm

The Mercury Ore market report has been fragmented into important regions that showcase worthwhile growth to the vendors Region 1 (Country 1, Country 2), region 2 (Country 1, Country 2) and region 3 (Country 1, Country 2). Each geographic segment has been assessed based on supply-demand status, distribution, and pricing. Further, the study provides information about the local distributors with which the market players could create collaborations in a bid to sustain production footprint.

Market Segment Analysis The research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type, the Mercury Ore market is segmented into High Concentrations Medium Concentration Low Concentration

Segment by Application Chemical Engineering Medicine

Global Mercury Ore Market: Regional Analysis The Mercury Ore market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026. The key regions covered in the Mercury Ore market report are: North America U.S. Canada Europe Germany France U.K. Italy Russia Asia-Pacific China Japan South Korea India Australia Taiwan Indonesia Thailand Malaysia Philippines Vietnam Latin America Mexico Brazil Argentina Middle East & Africa Turkey Saudi Arabia U.A.E Global Mercury Ore Market: Competitive Analysis This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019. The major players in global Mercury Ore market include: Turnstone Guizhou Mercury Including Wanfu Industry Co., LTD Mc Dermitt Guizhou Mercury

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2633884&source=atm

What does the Mercury Ore market report contain?

Readers can get the answers of the following questions while going through the Mercury Ore market report:

And many more

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2633884&licType=S&source=atm

Visit link:
Mercury Ore Market 2019 Industry by Type, by Application and by Region Forecast to 2023 - The Daily Chronicle

Read the Rest...

What you need to know to survive seasonal allergies in Maine – Bangor Daily News

§ September 19th, 2020 § Filed under Nano Medicine Comments Off on What you need to know to survive seasonal allergies in Maine – Bangor Daily News

Ragweed is one of the most common sources of the pollen behind seasonal allergies.

Nearly 20 million people in the country suffer to some degree from seasonal allergies, according to the U.S. Centers for Disease Control and Prevention. Call it what you want allergies, hay fever or allergic rhinitis the stuffy head, itchy eyes, painful sinuses and skin irritations can all flair up depending on whats in bloom in your region.

Knowing a bit about seasonal allergies in general and specific allergies, in particular, can go a long way in keeping any allergy season bearable.

Seasonal allergies happen when the bodys immune system goes into overdrive and overreacts to something in the environment, according to the American College of Allergies, Asthma and Immunology. From early spring to the first frosts of fall, the most common cause of seasonal allergic reactions is plant pollen.

When the pollen enters the body through the nose, mouth or eyes the body produces histamines to attack and kill off these invaders. In a non-allergic person, this all goes on quietly with no physical reaction. But for those people who have a heightened response to the release of histamines the body can react with sniffles, sneezes, itchy eyes, difficulty breathing, wheezing or inability to swallow.

Pollen is a tiny, even microscopic, powdery substance that fertilizes plants for reproduction. Its in flowers, trees, grasses and weeds. For many of these plants, the pollen is dispersed by wind and air currents which can blow them right up your nose, into your mouth or eyes and onto your clothes and skin.

As the term seasonal allergies implies, an individuals reactions to plant pollen can change or even vanish depending on what is in bloom at any particular time or season. So if you know you have allergies, its important to pay attention to what exactly is blooming and casting off pollen around you.

You can keep track of how much of what kind of pollen is in the air in your region by checking the daily pollen count. A pollen count measures the number of grains of specific plan pollen in a cubic meter of air. The higher the count, the more pollen is out there and the more likely it is to trigger seasonal allergies.

Online resources like pollen.com or weather.com issue daily reports on what plants are producing pollen and at what levels. The counts range numerically from zero to 12, which is very high.

The pollen count is affected by the weather. The airborne pollen grains can travel much farther and faster the lower the humidity and the higher the wind speeds meaning a higher count. On rainy or days with high humidity, the pollen is damp and heavy so it stays on the plant or on the ground and resulting in a lower pollen count.

Allergy season starts for some in April or May in Maine where most of the spring pollen comes from trees like pine, maple or oak. Those are quickly followed by dandelion pollen which often gets a boost when people mow their lawns and stir up that pollen.

As summer moves on, the grasses start to release pollen.

If its July, August or September in Maine and you are dealing with seasonal allergies, the likely culprit is ragweed. Seventeen species of ragweed grow in North America but the only one in the state is common ragweed (Ambrosia artemisiifolia). This annual grows up to 3 feet high with small green flowers.

It grows in fields, alongside the road, in parks and can even pop up between cracks in pavement or concrete. A single ragweed plant can produce up to 1 billion tiny pollen grains. Its one of the primary sources of allergic reactions in the country.

One of the best ways to avoid seasonal allergies is to avoid whatever it is you are allergic to. Depending on what that is, however, that strategy may not be practical. But try to avoid as best you can walking directly through or under any plant that is blooming or dispersing pollen.

Matthew Derosby, a physician assistant at Northern Light Health Family Medicine of Brewer, suggested if you have gone outside and come into contact with the pollen, remove your clothes when you get inside and hop into the shower to rinse off.

Inside the home avoid opening windows if there is a breeze that can blow any pollen inside and instead use an air conditioning unit to cool and filter indoor air if needed.

From a medical standpoint, there are several over-the-counter antihistamine drops, pills and ointments that offer relief from seasonal allergy symptoms.

The thing to remember with these is they need to be used every day and overtime to reduce the symptoms and then prevent them, Debrosy said. That is the mistake I see people make they buy the product, use it a couple of days and when its not working they give up. You have to use them a full two weeks before you see the effect.

For immediate relief, there are over-the-counter oral medications both sedating like Benadryl and non-sedating like Claratin or Zyrtec that reduce symptoms throughout the body.

While not tested by the U.S. Federal Drug Administration, there are some home remedies that people swear by. The most common is eating honey produced by local bees. The reasoning is that by ingesting honey made with nectar the bees collected from allergy-triggering plants. Debrosy said he cant speak to the medicinal value of honey, but said he has patients who swear by it.

Other home remedies include eating fruits like papaya or pineapples that contain the enzyme bromelain. Some natural healers believe the enzyme reduces swelling, thereby opening up nasal passages. Anecdotal evidence has also shown that probiotics like those in yogurt can help reduce the symptoms of seasonal allergies. However, there isnt data to confirm the effectiveness of natural remedies.

Read more here:
What you need to know to survive seasonal allergies in Maine - Bangor Daily News

Read the Rest...

Atmospheric Filling Machine Market: Quantitative Analysis From 2019 To 2023 To Enable The Stakeholders To Capitalize On The Prevailing Market…

§ September 19th, 2020 § Filed under Nano Medicine Comments Off on Atmospheric Filling Machine Market: Quantitative Analysis From 2019 To 2023 To Enable The Stakeholders To Capitalize On The Prevailing Market…

The Atmospheric Filling Machine market research focuses on the market structure and various factors (positive and negative) affecting the growth of the market. The study encloses a precise evaluation of the Atmospheric Filling Machine market, including growth rate, current scenario, and volume inflation prospects, on the basis of DROT and Porters Five Forces analyses. In addition, the Atmospheric Filling Machine market study provides reliable and authentic projections regarding the technical jargon.

Atmospheric Filling Machine Market Research, in its recent market report, suggests that the Atmospheric Filling Machine market report is set to exceed US$ xx Mn/Bn by 2029. The report finds that the Atmospheric Filling Machine market registered ~US$ xx Mn/Bn in 2018 and is spectated to grow at a healthy CAGR over the foreseeable period. This Atmospheric Filling Machine market study considers 2018 as the base year, 2019 as the estimated year, and 2019 2029 as the forecast timeframe.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.researchmoz.com/enquiry.php?type=S&repid=2630081&source=atm

The Atmospheric Filling Machine market study answers critical questions including:

The content of the Atmospheric Filling Machine market report includes the following insights:

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2630081&source=atm

Market Segment Analysis The research report includes specific segments by Type and by Application. Each type provides information about the production during the forecast period of 2015 to 2026. Application segment also provides consumption during the forecast period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type Semiautomatic Fully Automatic

Segment by Application Medicine Daily chemical Food Others

Global Atmospheric Filling Machine Market: Regional Analysis The report offers in-depth assessment of the growth and other aspects of the Atmospheric Filling Machine market in important regions, including the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, Taiwan, Southeast Asia, Mexico, and Brazil, etc. Key regions covered in the report are North America, Europe, Asia-Pacific and Latin America. The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue, production, and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2015 to 2026. These analyses will help the reader to understand the potential worth of investment in a particular region.

Global Atmospheric Filling Machine Market: Competitive Landscape This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and production by manufacturers during the forecast period of 2015 to 2019.

All the players running in the global Atmospheric Filling Machine market are elaborated thoroughly in the Atmospheric Filling Machine market report on the basis of R&D developments, distribution channels, industrial penetration, manufacturing processes, and revenue. In addition, the report examines, legal policies, and comparative analysis between the leading and emerging Atmospheric Filling Machine market players.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2630081&licType=S&source=atm

Why choose Atmospheric Filling Machine market Report?

Read more from the original source:
Atmospheric Filling Machine Market: Quantitative Analysis From 2019 To 2023 To Enable The Stakeholders To Capitalize On The Prevailing Market...

Read the Rest...

Thrombin (Human) Market Research Insights 2019 Global Industry Outlook Shared in Detailed Report, Forecast to 2025 – Scientect

§ September 19th, 2020 § Filed under Nano Medicine Comments Off on Thrombin (Human) Market Research Insights 2019 Global Industry Outlook Shared in Detailed Report, Forecast to 2025 – Scientect

Growth Prospects of the Global Thrombin (Human) Market

The comprehensive study on the Thrombin (Human) market provides crucial insights to the stakeholders who are vying to solidify their presence in the current and future market landscape. The various factors that are likely to shape the course of the Thrombin (Human) market over the next decade are thoroughly analyzed in the report. The study represents the market share in terms of US$ XX Mn/Bn and volume (XX units).

The report splits the global Thrombin (Human) market based on product type wherein a complete analysis of the various products including, product 1, product 2, product 3, and product 4 is provided. The market share of each product, the adoption rate, pricing analysis and more is included in the report along with accurate tables, graphs, and figures. The market is further segmented on the basis of end use and tracks the scope of each end use over the stipulated time frame. The various end uses covered in the report include end use 1, end use 2, end use 3, and end use 4.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2634744&source=atm

The report addresses the following queries pertaining to the Thrombin (Human) market:

Application analysis

The presented study dissects the global Thrombin (Human) market on the basis of application and provides accurate data related to the size, share, and revenue growth of each application over the forecast period.

The quantitative and qualitative analysis of the market scenario in different regions and key success factors impacting the growth of the market in each region is provided in the market study. The different regions covered in the report include:

Market Segment Analysis The research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth. Segment by Type, the Thrombin (Human) market is segmented into 500IU/Vial 1000IU/Vial 2500IU/Vial

Segment by Application Biotechnology Medicine Microbiology Other

Global Thrombin (Human) Market: Regional Analysis The Thrombin (Human) market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026. The key regions covered in the Thrombin (Human) market report are: North America U.S. Canada Europe Germany France U.K. Italy Russia Asia-Pacific China Japan South Korea India Australia Taiwan Indonesia Thailand Malaysia Philippines Vietnam Latin America Mexico Brazil Argentina Middle East & Africa Turkey Saudi Arabia U.A.E Global Thrombin (Human) Market: Competitive Analysis This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019. The major players in global Thrombin (Human) market include: Baxter AMRESCO Inc BD Biosciences Life Technologies Corporation PromoCell GmbH Sigma-Aldrich Corporation Vitrolife AB CSL Bayer Grifols Octapharma Shanghai RAAS Hualan Biological

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2634744&source=atm

Essential findings of the market study:

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2634744&licType=S&source=atm

Original post:
Thrombin (Human) Market Research Insights 2019 Global Industry Outlook Shared in Detailed Report, Forecast to 2025 - Scientect

Read the Rest...

Nanomedicine Seen As A Promising Approach For Diagnosis and Treatment Against COVID – PRNewswire

§ September 19th, 2020 § Filed under Nano Medicine Comments Off on Nanomedicine Seen As A Promising Approach For Diagnosis and Treatment Against COVID – PRNewswire

PLAM BEACH, Fla., Sept. 16, 2020 /PRNewswire/ --The National Institute for Health (NIH) is at the heart of the emerging and rapidly evolving war against the global pandemic. They constantly update the public on the latest information on research for a vaccine and therapies to fight the virus. A recent report from them shone the light on a specific promising therapeutic approach nanomedicine. The NIH said that nanomedicine is a promising approach fordiagnosis, treatment and prophylaxis against COVID-19. They said that: "The COVID-19pandemic caused by the newly emerged severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) puts the world in an unprecedented crisis, leaving behind huge human losses and deep socioeconomic damages. Due to the lack of specific treatment against SARS-CoV-2, effective vaccines and antiviral agents are urgently needed to properly restrain the COVID-19 pandemic. Repositioned drugs such asremdesivir have revealed a promising clinical efficacy against COVID-19. Interestingly, nanomedicine as a promising therapeutic approach could effectively help win the battle between coronaviruses and host cells."Mentioned in today's commentary include: NanoViricides, Inc. (NYSE: NNVC), Immunomedics(NASDAQ: IMMU), Gilead Sciences, Inc. (NASDAQ: GILD), Inovio Pharmaceuticals, Inc. (NASDAQ: INO), Novavax, Inc. (NASDAQ: NVAX).

Due to a lack of approved vaccines and specific treatments only preventive measures can currently be applied. Currently, development of an effective vaccine and specific treatment is the main concern for researchers worldwide to fight the current COVID-19 and any future mutations. Understanding the coronaviral genome and the processes of viral replication and pathogenesis will enable researchers to develop specific drugs and vaccines. So researchers are turning to nanomedicine, one of the most important and emerging fields of modern science.

NanoViricides, Inc. (NYSE American: NNVC) Breaking News: NanoViricides Nominates a Novel Candidate for Advancing Into Clinical Trials for Treatment of COVID-19 NanoViricides, a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has nominated a clinical drug candidate for the treatment of COVID-19, thus further advancing its COVID-19 program closer to human clinical trials.

The Company has accelerated its drug development program for COVID-19 with the goal of creating the most effective medicine to obtain regulatory approval for emergency use in the COVID-19 pandemic in the shortest timeline feasible, after achieving proof of concept of broad-spectrum anti-coronavirus effectiveness of test candidates. The Company therefore aggressively worked to harness the full power of the nanoviricides nanomedicine platform to achieve these objectives.

A curative treatment for a virus such as SARS-CoV-2 coronavirus would require a multi-faceted attack that shuts down (i) ability of the virus to infect host cells and simultaneously, (ii) ability of the virus to multiply inside the host cells. The nanoviricide platform enables direct multi-point attack on the virus that is designed to disable the virus and its ability to infect new cells. At the same time, a nanoviricide is also capable of carrying payload in its "belly" (inside the micelle) that can be chosen to affect the ability of the virus to replicate. The nanoviricide is designed to protect the payload from metabolism in circulation. Thus, the nanoviricide platform provides an important opportunity to develop a curative treatment against SARS-CoV-2, the cause of COVID-19 spectrum of pathologies.

The clinical candidate the Company has chosen is identified as NV-CoV-1-R. It is made up of a nanoviricide that we have found to possess broad-spectrum anti-coronavirus activity, now identified as NV-CoV-1, and remdesivir encapsulated inside the core of NV-CoV-1. NV-CoV-1 itself is designed to attack the virus particles themselves, and possibly would also attack infected cells that display the virus antigen S-protein, while sparing normal (uninfected) cells that do not display the S-protein. Additionally, remdesivir is widely understood to attack the replication cycle of the virus inside cells. Thus the combined attack enabled by NV-CoV-1-R on the virus could prove to be a cure for the infection and the disease, provided that the necessary dosage level can be attained without undue adverse effects. Human clinical trials will be required to determine the safety and effectiveness of NV-CoV-1-R.

Remdesivir is a well-known antiviral drug (developed by Gilead) that has been approved for emergency use treatment of SARS-CoV-2 infection or COVID-19 in several countries. NV-CoV-1 is a novel agent that is being used as an adjuvant to remdesivir in creating NV-CoV-1-R, to improve the overall effectiveness. It is well known that remdesivir suffers from rapid metabolism in circulation that breaks down the prodrug to its nucleoside form which is not readily phosphorylated. The Company anticipates that encapsulation in NV-CoV-1 may protect remdesivir from this rapid metabolism. If this happens, the effective level and stability of remdesivir in the body would increase. This increase may lead to increased effectiveness if there are no adverse effects. Such increased effectiveness, if found, may also allow reduction in the required dosage of remdesivir in the encapsulated form, i.e. as NV-CoV-1-R. In this sense, NV-CoV-1 can be viewed to act as an adjuvant that enhances the effect of remdesivir, a known antiviral against SARS-CoV-2.

"This is an extremely important milestone for the Company," said Anil R. Diwan, PhD, President and Executive Chairman of the Company, adding, "We look forward to rapid development of the IND enabling core safety pharmacology studies and, thereafter, human clinical development on an accelerated timeline in these trying times of the pandemic." Read the full press release by going to: http://www.nanoviricides.com/companynews.html

In other biotech news in the markets this week:

Immunomedics(NASDAQ: IMMU) and Gilead Sciences, Inc. (NASDAQ: GILD)recently announcedthat the companies have entered into a definitive agreement pursuant to which Gilead will acquire Immunomedics for $88.00 per share in cash. The transaction, which values Immunomedics at approximately $21 billion, was unanimously approved by both the Gilead and Immunomedics Boards of Directors and is anticipated to close during the fourth quarter of 2020.

The agreement will provide Gilead with TrodelvyTM(sacituzumab govitecan-hziy), a first-in-class Trop-2 directed antibody-drug conjugate (ADC) that was granted accelerated approval by the U.S. Food and Drug Administration (FDA) in April for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. Immunomedics plans to submit a supplemental Biologics License Application (BLA) to support full approval of Trodelvy in the United States in the fourth quarter of 2020. Immunomedics is also on track to file for regulatory approval in Europe in the first half of 2021.

"This acquisition represents significant progress in Gilead's work to build a strong and diverse oncology portfolio. Trodelvy is an approved, transformational medicine for a form of cancer that is particularly challenging to treat. We will now continue to explore its potential to treat many other types of cancer, both as a monotherapy and in combination with other treatments," said Daniel O'Day, Chairman and Chief Executive Officer, Gilead Sciences. "We look forward to welcoming the talented Immunomedics team to Gilead so we can continue to advance this important new medicine for the benefit of patients with cancer worldwide."

INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases and cancer, recently announced that Thermo Fisher Scientific, the world leader in serving science, has signed a letter of intent to manufacture INOVIO's DNA COVID-19 vaccine candidate INO-4800.

Thermo Fisherjoins other contract development and manufacturing organizations in INOVIO's global manufacturing consortium, enabling INOVIO to potentially scale commercial production of INO-4800. With its consortium of third-party manufacturers, INOVIO plans to have 1001million doses of INO-4800 manufactured in 2021, subject to FDA approval of INO-4800 for use as a COVID-19 vaccine.Thermo Fisherplans to manufacture INO-4800 drug substance as well as perform fill and finish of INO-4800 drug product at its commercial facilities in the US. At peak capacity,Thermo Fisherprojects that it could produce at least 100 million doses of INO-4800 annually.

Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, recently announced an amendment to its existing agreement with Serum Institute of India Private Limited (SIIPL) under which SIIPL will also manufacture the antigen component of NVXCoV2373, Novavax' COVID19 vaccine candidate. With this agreement, Novavax increases its manufacturing capacity of NVX-CoV2373 to overtwo billion doses annually, when all planned capacity has been brought online by mid-2021. NVXCoV2373 is a stable, prefusion protein made using Novavax' recombinant protein nanoparticle technology and includes Novavax' proprietary MatrixM adjuvant.

"Today's agreement with Serum Institute enhances Novavax' commitment to equitable global delivery of our COVID-19 vaccine. With this arrangement, we have now put in place a global supply chain that includes the recently acquired Praha Vaccines and partnerships with leading biologics manufacturers, enabling production on three continents," said Stanley C. Erck, President and Chief Executive Officer of Novavax. "We continue to work with extraordinary urgency to develop our vaccine, now in Phase 2 clinical trials, and for which we anticipate starting Phase 3 efficacy trials around the world in the coming weeks."

DISCLAIMER: FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.FNM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM was compensated twenty five hundred dollars for news coverage of current press release issued by NanoViricides, Inc. by a non-affiliated third party.FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Contact Information: Media Contact email: [emailprotected] +1(561)325-8757

SOURCE FinancialNewsMedia.com

See original here:
Nanomedicine Seen As A Promising Approach For Diagnosis and Treatment Against COVID - PRNewswire

Read the Rest...

R&D Activities to Fast-track the Growth of the Healthcare Nanotechnology (Nanomedicine) Market Between 2015 2021 – The Daily Chronicle

§ September 19th, 2020 § Filed under Nano Medicine Comments Off on R&D Activities to Fast-track the Growth of the Healthcare Nanotechnology (Nanomedicine) Market Between 2015 2021 – The Daily Chronicle

Persistence Market Research recently published a market study that sheds light on the growth prospects of the global Healthcare Nanotechnology (Nanomedicine) market during the forecast period (20XX-20XX). In addition, the report also includes a detailed analysis of the impact of the novel COVID-19 pandemic on the future prospects of the Healthcare Nanotechnology (Nanomedicine) market. The report provides a thorough evaluation of the latest trends, market drivers, opportunities, and challenges within the global Healthcare Nanotechnology (Nanomedicine) market to assist our clients arrive at beneficial business decisions.

The Healthcare Nanotechnology (Nanomedicine) market study is a well-researched report encompassing a detailed analysis of this industry with respect to certain parameters such as the product capacity as well as the overall market remuneration. The report enumerates details about production and consumption patterns in the business as well, in addition to the current scenario of the Healthcare Nanotechnology (Nanomedicine) market and the trends that will prevail in this industry.

Request Sample Report @ https://www.persistencemarketresearch.co/samples/6370

What pointers are covered in the Healthcare Nanotechnology (Nanomedicine) market research study?

The Healthcare Nanotechnology (Nanomedicine) market report Elucidated with regards to the regional landscape of the industry:

The geographical reach of the Healthcare Nanotechnology (Nanomedicine) market has been meticulously segmented into United States, China, Europe, Japan, Southeast Asia & India, according to the report.

The research enumerates the consumption market share of every region in minute detail, in conjunction with the production market share and revenue.

Also, the report is inclusive of the growth rate that each region is projected to register over the estimated period.

The Healthcare Nanotechnology (Nanomedicine) market report Elucidated with regards to the competitive landscape of the industry:

The competitive expanse of this business has been flawlessly categorized into companies such as

Key players in the global nanomedicine market include: Abbott Laboratories, CombiMatrix Corporation, GE Healthcare, Sigma-Tau Pharmaceuticals, Inc., Johnson & Johnson, Mallinckrodt plc, Merck & Company, Inc., Nanosphere, Inc., Pfizer, Inc., Celgene Corporation, Teva Pharmaceutical Industries Ltd., and UCB (Union chimique belge) S.A.

Key geographies evaluated in this report are:

Key features of this report

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/6370

Exclusive details pertaining to the contribution that every firm has made to the industry have been outlined in the study. Not to mention, a brief gist of the company description has been provided as well.

Substantial information subject to the production patterns of each firm and the area that is catered to, has been elucidated.

The valuation that each company holds, in tandem with the description as well as substantial specifications of the manufactured products have been enumerated in the study as well.

The Healthcare Nanotechnology (Nanomedicine) market research study conscientiously mentions a separate section that enumerates details with regards to major parameters like the price fads of key raw material and industrial chain analysis, not to mention, details about the suppliers of the raw material. That said, it is pivotal to mention that the Healthcare Nanotechnology (Nanomedicine) market report also expounds an analysis of the industry distribution chain, further advancing on aspects such as important distributors and the customer pool.

The Healthcare Nanotechnology (Nanomedicine) market report enumerates information about the industry in terms of market share, market size, revenue forecasts, and regional outlook. The report further illustrates competitive insights of key players in the business vertical followed by an overview of their diverse portfolios and growth strategies.

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/6370

Some of the Major Highlights of TOC covers:

Read more:
R&D Activities to Fast-track the Growth of the Healthcare Nanotechnology (Nanomedicine) Market Between 2015 2021 - The Daily Chronicle

Read the Rest...

Healthcare Nanotechnology Market Insights Competitive Analysis and Future Demand and Revenue Forecast to 2024 | Key Companies: Amgen, Stryker, Teva…

§ September 19th, 2020 § Filed under Nano Medicine Comments Off on Healthcare Nanotechnology Market Insights Competitive Analysis and Future Demand and Revenue Forecast to 2024 | Key Companies: Amgen, Stryker, Teva…

Healthcare Nanotechnology Market2020-2025 report offerscomprehensive quantitative and qualitative market analysis. This report has been prepared under the continuous observation of the global market situation. This report has been formulated to give our clients the most up to date data and analyses of the Healthcare Nanotechnology Market. The impact on the enterprises and business development, distribution by region and global level is assessed in the report.

Top Companies are covering This Report:-

Amgen Stryker Teva Pharmaceuticals UCB Roche Abbott Merck & Co Celgene Biogen Sanofi Leadiant Biosciences Shire Kyowa Hakko Kirin Gilead Sciences Johnson & Johnson 3M Company Endo International Smith & Nephew Pfizer Ipsen

The research process involved the study of various factors affecting the industry such as government policy, market environment, competitive landscape, historical data, existing trends in the market, and market risks, opportunities, market barriers and challenges.

Reports Intellect projects Healthcare Nanotechnology Market based on elite players, present, past, and forecast data for the coming years which will act as a profitable guide for all the market competitors. The study includes growth trends, micro- economic and macro-economic indicators in detail and the report has been assessed with the help of PESTEL analysis and other essential analyses operating in the Healthcare Nanotechnology Market. Top-down and bottom-up approaches are used to validate the global Healthcare Nanotechnology market size and estimate the market size for Company, regions segments, product segments and Application.

Get Sample PDF Brochure @https://www.reportsintellect.com/sample-request/905451

The report offers all the essential data for players to secure a position of strength in the market, all while creating a comprehensive action plan. Our analysts here at Reports Intellect have used advanced primary and secondary research techniques to create the most up to date assessment of data on the Healthcare Nanotechnology Market which opens up a plethora of new opportunities to create new strategies to gain leverage over the competition.

Type Coverage:

Nanomedicine Nano Medical Devices Nano Diagnosis Others Nanomedicine has the highest percentage of revenue by type, with more than 86% in 2019.

Application Coverage:

Anticancer CNS Product Anti-infective Others According to the application, anticancer and CNS products accounted for 17.56% and 22.70% of the market in 2019 respectively.

Market Segment by Regions, regional analysis covers

North America Country (United States, Canada)

South America

Asia Country (China, Japan, India, Korea)

Europe Country (Germany, UK, France, Italy)

Other Country (Middle East, Africa, GCC)

Discount PDF Brochure @https://www.reportsintellect.com/discount-request/905451

Why us:

Reasons to buy:

About Us:-

Contact Us:

Sales@reportsintellect.com

PH + 1-706-996-2486

US Address:

225 Peachtree Street NE,

Suite 400,

Atlanta, GA 30303

Excerpt from:
Healthcare Nanotechnology Market Insights Competitive Analysis and Future Demand and Revenue Forecast to 2024 | Key Companies: Amgen, Stryker, Teva...

Read the Rest...

Global Nanomedicine market (Covid 19 Update) Competitive Insights, Trends and Demand Growth 2020 to 2027 – Good Night, Good Hockey

§ September 15th, 2020 § Filed under Nano Medicine Comments Off on Global Nanomedicine market (Covid 19 Update) Competitive Insights, Trends and Demand Growth 2020 to 2027 – Good Night, Good Hockey

DBMR has added a new report titled Global Nanomedicine market withdata Tables for historical and forecast years represented with Chats & Graphs spread through Pages with easy to understand detailed analysis. Global Nanomedicine marketreport provides exact information about market trends, industrial changes, and consumer behaviour etc. The report assists in outlining brand awareness, market landscape, possible future issues, industry trends and customer behaviour about industry which eventually leads to advanced business strategies. Being a verified and reliable source of information, this market research report offers a telescopic view of the existing market trends, emerging products, situations and opportunities that drives the business in the right direction of success. Thereport has been framed with the proper use of tools like SWOT analysis and Porters Five Forces analysis methods.

Global nanomedicine marketis registering a healthy CAGR of 15.50% in the forecast period of 2019-2026. This rise in the market value can be attributed to increasing number of applications and wide acceptance of the product globally. There is a significant rise in the number of researches done in this field which accelerate growth of nanomedicine market globally.

Get Sample Report + All Related Graphs & Charts @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-nanomedicine-market

Key Market Competitors

Few of the major market competitors currently working in the global nanomedicine market are Abbott, Invitae Corporation, General Electric Company, Leadiant Biosciences, Inc., Johnson & Johnson Services, Inc., Mallinckrodt, Merck Sharp & Dohme Corp., NanoSphere Health Sciences, Inc., Pfizer Inc., CELGENE CORPORATION, Teva Pharmaceutical Industries Ltd., Gilead Sciences, Inc., Amgen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Novartis AG, F. Hoffmann-La Roche Ltd., Luminex Corporation, Eli Lilly and Company, Nanobiotix, Sanofi, UCB S.A., Ablynx among others.

Competitive Landscape

Global nanomedicine market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of nanomedicine market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Insights in the report:

Complete and distinct analysis of the market drivers and restraints

Key Market players involved in this industry

Detailed analysis of the Market Segmentation

Competitive analysis of the key players involved

Market Drivers are Restraints

Grab Your Report at an Impressive 30% Discount! Please click Here @https://www.databridgemarketresearch.com/request-a-discount/global-nanomedicine-market

Market Segmentation:-

By Product Type

By Application

By Indication

By Modality

To comprehend Global Nanomedicine market dynamics in the world mainly, the worldwide Nanomedicine market is analyzed across major global regions.

Actual Numbers & In-Depth Analysis, Business opportunities, Market Size Estimation Available in Full Report.

Some of the Major Highlights of TOC covers:

Chapter 1: Methodology & Scope

Definition and forecast parameters

Methodology and forecast parameters

Data Sources

Chapter 2: Executive Summary

Business trends

Regional trends

Product trends

End-use trends

Chapter 3: Industry Insights

Industry segmentation

Industry landscape

Vendor matrix

Technological and innovation landscape

For More Insights Get Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-nanomedicine-market

Nanomedicine Market report effectively provides required features of the global market for the population and for the business looking people for mergers & acquisitions, making investments, new vendors or concerned in searching for the appreciated global market research facilities. It offers sample on the size, offer, and development rate of the market. The Nanomedicine report provides the complete structure and fundamental overview of the industry market.

Note: If you have any special requirements, please let us know and we will offer you the report as you want.

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:Corporatesales@databridgemarketresearch.com

The rest is here:
Global Nanomedicine market (Covid 19 Update) Competitive Insights, Trends and Demand Growth 2020 to 2027 - Good Night, Good Hockey

Read the Rest...

Nanomedicine Market Provides in-depth analysis of the Nanomedicine Industry, with current trends and future estimations to elucidate the investment…

§ September 15th, 2020 § Filed under Nano Medicine Comments Off on Nanomedicine Market Provides in-depth analysis of the Nanomedicine Industry, with current trends and future estimations to elucidate the investment…

Nanomedicine Market Overview:

Reports and Data has recently published a new research study titled Global Nanomedicine Market that offers accurate insights for the Nanomedicine market formulated with extensive research. The report explores the shifting focus observed in the market to offer the readers data and enable them to capitalize on market development. The report explores the essential industry data and generates a comprehensive document covering key geographies, technology developments, product types, applications, business verticals, sales network and distribution channels, and other key segments.

The report is further furnished with the latest market changes and trends owing to the global COVID-19 crisis. The report explores the impact of the crisis on the market and offers a comprehensive overview of the segments and sub-segments affected by the crisis. The study covers the present and future impact of the pandemic on the overall growth of the industry.

Get a sample of the report @ https://www.reportsanddata.com/sample-enquiry-form/1048

Competitive Landscape:

The global Nanomedicine market is consolidated owing to the existence of domestic and international manufacturers and vendors in the market. The prominent players of the key geographies are undertaking several business initiatives to gain a robust footing in the industry. These strategies include mergers and acquisitions, product launches, joint ventures, collaborations, partnerships, agreements, and government deals. These strategies assist them in carrying out product developments and technological advancements.

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

Arrowhead Pharmaceuticals Inc. AMAG Pharmaceuticals, Bio-Gate AG, Celgene Corporation, and Johnson & Johnson.

An extensive analysis of the market dynamics, including a study of drivers, constraints, opportunities, risks, limitations, and threats have been studied in the report. The report offers region-centric data and analysis of the micro and macro-economic factors affecting the growth of the overall Nanomedicine market. The report offers a comprehensive assessment of the growth prospects, market trends, revenue generation, product launches, and other strategic business initiatives to assist the readers in formulating smart investment and business strategies.

To read more about the report, visit @ https://www.reportsanddata.com/report-detail/nanomedicine-market

Product Outlook (Revenue, USD Billion; 2017-2027)

Drug Delivery System Outlook (Revenue, USD Billion; 2017-2027)

Application Outlook (Revenue, USD Billion; 2017-2027)

Request a discount on the report @ https://www.reportsanddata.com/discount-enquiry-form/1048

Key Coverage in the Nanomedicine Market Report:

Thank you for reading our report. Please get in touch with us if you have any queries regarding the report or its customization. Our team will make sure the report is tailored to meet your requirements.

Take a look at other reports from Reports and Data on PR Newswire:

Hydroxycitronellal Market: Hydroxycitronellal Market To Reach USD 192.7 Million By 2027

Sterile Filtration Market: Sterile Filtration Market To Reach USD 8.48 Billion By 2027 | CAGR: 7.7%

Tissue Diagnostics Market: Tissue Diagnostics Market To Reach USD 5.02 Billion By 2027

UV-C Robot Market: UV-C Robot Market to Reach USD 1.46 Billion by 2027

About Us:

Our in-house experts assist our clients with advice based on their proficiency in the market that helps them in creating a compendious database for the clients. Our team offers expert insights to clients to guide them through their business ventures. We put in rigorous efforts to keep our clientele satisfied and focus on fulfilling their demands to make sure that the end-product is what they desire. We excel in diverse fields of the market and with our services extending to competitive analysis, research and development analysis, and demand estimation among others, we can help you invest your funds in the most beneficial areas for research and development. You can rely on us to provide every significant detail you might need in your efforts to make your business flourish.

Contact Us:

John Watson

Head of Business Development

Reports and Data|Web:www.reportsanddata.com

Direct Line:+1-212-710-1370

E-mail:[emailprotected]

Connect with us:Blogs|LinkedIn|Twitter

Read the original here:
Nanomedicine Market Provides in-depth analysis of the Nanomedicine Industry, with current trends and future estimations to elucidate the investment...

Read the Rest...

Tottenham Acquisition I Limited Announces Filing of a Registration Statement on Form S-4 in Connection with its Proposed Business Combination with…

§ September 12th, 2020 § Filed under Nano Medicine Comments Off on Tottenham Acquisition I Limited Announces Filing of a Registration Statement on Form S-4 in Connection with its Proposed Business Combination with…

NEW YORK, Sept. 10, 2020 /PRNewswire/ -- Tottenham Acquisition I Limited (Nasdaq: TOTA, TOTAU, TOTAW, TOTAR) ("Tottenham"), a publicly traded special purpose acquisition company, announced today that its subsidiary, Chelsea Worldwide Inc., has filed with the U.S. Securities and Exchange Commission ("SEC") a registration statement on Form S-4 (the "Registration Statement"), which includes a preliminary proxy statement/consent solicitation statement/prospectus, in connection with its recently-announced proposed business combination with Clene Nanomedicine, Inc. ("Clene"), a clinical-stage biopharmaceutical company developing a potential therapeutic nanocatalyst for the treatment of neurodegenerative diseases in addition to a nanotechnology based-therapy with antiviral applications.

Tottenham's ordinary shares are currently traded on Nasdaq under the symbol "TOTA". In connection with the closing of the transaction, Tottenham intends to change its name to Clene Inc., reincorporate in Delaware (by merging with Chelsea Worldwide Inc.) and remain Nasdaq-listed under a new ticker symbol. Completion of the transaction is subject to approval by Tottenham shareholders, Clene's stockholders, the Registration Statement being declared effective by the SEC, a concurrent closing of private placements and other customary closing conditions.

Chardan is acting as the M&A advisor to Tottenham. LifeSci Capital LLC is acting as the M&A advisor to Clene. Loeb & Loeb LLP is acting as legal advisor to Tottenham. Kirkland & Ellis LLP along with Stoel Rives LLP, Clene's local counsel, are acting as legal advisors to Clene.

About Clene Nanomedicine, Inc.

Clene Nanomedicine, Inc. is a privately held, clinical-stage biopharmaceutical company focused on the development of unique therapeutic candidates for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally-administered neurotherapeutic drugs.Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. Founded in 2013, the company is based inSalt Lake City, Utahwith R&D and manufacturing operations located inNorth East, Maryland. For more information, please visitwww.clene.com.

About Tottenham Acquisition I Limited

Tottenham Acquisition I Limited is a blank check company formed for the purpose of acquiring, engaging in a share exchange, share reconstruction and amalgamation with, purchasing all or substantially all of the assets of, entering into contractual arrangements with, or engaging in any other similar business combination with one or more businesses or entities. Tottenham's efforts to identify a prospective target business were not limited to a particular industry or geographic region, although the company initially focused on operating businesses in the TMT (Technology, Media, Telecom), education, e-commerce, health-care and consumer goods industries with primary operations inAsia(with an emphasis inChina).

Forward-Looking Statements

This press release contains, and certain oral statements made by representatives of Tottenham, Clene, and their respective affiliates, from time to time may contain, "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Tottenham's and Clene's actual results may differ from their expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "might" and "continues," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, Tottenham's and Clene's expectations with respect to future performance and anticipated financial impacts of the business combination, the satisfaction of the closing conditions to the business combination and the timing of the completion of the business combination. These forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from expected results. Most of these factors are outside the control of Tottenham or Clene and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement relating to the proposed business combination; (2) the outcome of any legal proceedings that may be instituted against Tottenham or Clene following the announcement of the Merger Agreement and the transactions contemplated therein; (3) the inability to complete the business combination, including due to failure to obtain approval of the shareholders of Tottenham or other conditions to closing in the Merger Agreement; (4) delays in obtaining or the inability to obtain necessary regulatory approvals (including approval from regulators, as applicable) required to complete the transactions contemplated by the Merger Agreement; (5) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement or could otherwise cause the transaction to fail to close; (6) the inability to obtain or maintain the listing of the post-acquisition company's ordinary shares on NASDAQ following the business combination; (7) the risk that the business combination disrupts current plans and operations as a result of the announcement and consummation of the business combination; (8) the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably and retain its key employees; (9) costs related to the business combination; (10) changes in applicable laws or regulations; (11) the possibility that Clene or the combined company may be adversely affected by other economic, business, and/or competitive factors; and (12) other risks and uncertainties identified in the Form S-4 filed by Chelsea Worldwide relating to the business combination, including those under "Risk Factors" therein, and in other filings with the Securities and Exchange Commission ("SEC") made by Tottenham and Clene. Tottenham and Clene caution that the foregoing list of factors is neither exclusive nor exhaustive. Tottenham and Clene caution readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Neither Tottenham or Clene undertakes or accepts any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based, subject to applicable law. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.

Important Information

Chelsea Worldwide Inc., Tottenham, and their respective directors, executive officers and employees and other persons may be deemed to be participants in the solicitation of proxies from the holders of Tottenham ordinary shares in respect of the proposed transaction described herein. Information about Tottenham's directors and executive officers and their ownership of Tottenham's ordinary shares is set forth in Tottenham's Annual Report on Form 10-K filed with the SEC, as modified or supplemented by any Form 3 or Form 4 filed with the SEC since the date of such filing. Other information regarding the interests of the participants in the proxy solicitation are included in the Form S-4 pertaining to the proposed transaction. These documents can be obtained free of charge from the sources indicated below.

In connection with the transaction described herein, Chelsea Worldwide Inc. will file relevant materials with the SEC including a Registration Statement on Form S-4. Promptly after the Registration Statement is declared effective, Tottenham will mail the proxy statement and a proxy card to each shareholder entitled to vote at the extraordinary general meeting relating to the transaction. INVESTORS AND SECURITY HOLDERS OF TOTTENHAM ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE TRANSACTION THAT TOTTENHAM WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT TOTTENHAM, CLENE AND THE TRANSACTION. The proxy statement/consent solicitation/prospectus and other relevant materials in connection with the transaction (when they become available), and any other documents filed by Tottenham with the SEC, may be obtained free of charge at the SEC's website (www.sec.gov).

SOURCE Tottenham Acquisition I Limited

Read more:
Tottenham Acquisition I Limited Announces Filing of a Registration Statement on Form S-4 in Connection with its Proposed Business Combination with...

Read the Rest...

Trillium follows positive data and a $25M equity investment with a $130M offering – BioWorld Online

§ September 12th, 2020 § Filed under Nano Medicine Comments Off on Trillium follows positive data and a $25M equity investment with a $130M offering – BioWorld Online

Trillium Therapeutics Inc. has played a hot hand this week. The Cambridge, Mass.-based immune oncology company followed Sept. 8s positive data from two dose-escalation phase I studies targeting CD47 by pricing a $130 million underwritten public offering of 10 million common shares at $13 each. The company said it plans to spend the net proceeds for ongoing and planned clinical trials. Gross proceeds are expected to be around $130 million, with the deal closing about Sept. 16. In addition to the upbeat data and offering, Pfizer Inc. has kicked in a $25 million equity investment in Trillium. Despite lackluster stock movement on Sept. 11, Trillium (NASDAQ:TRIL) posted a solid week. On Sept. 9, share value popped up 46% to close at $13.59 each. At midday Sept. 11, shares were going for $13.90.

Results from the first trial testing the oral autotaxin inhibitor, ziritaxestat, in adults with diffuse cutaneous systemic sclerosis have encouraged its originator, Galapagos NV, to explore next steps for the program, it said Friday. Need in the indication is high, with no drugs currently approved to treat the overall disease. Galapagos' U.S.-listed shares (NASDAQ:GLPG) climbed 6.2% by midday as the news appeared to expand the potential applications of the candidate, a key element in the company's decade-long alliance with Gilead Sciences Inc. that is also in development for idiopathic pulmonary fibrosis.

LONDON The international commission convened in the aftermath of Chinese scientist He Jiankuis shock announcement of the birth of gene edited twins has set a possible course to approval of heritable gene editing, but said the technique is far from ready for use. At this time, it is not possible to specify how to move from research to clinical application because it is not possible to make precise edits, or avoid introducing off-target effects, the committee said.

Researchers at the Diabetes Institute of the University of Washington and the University of Copenhagen have implicated the brainin the ability of intracranial injections of fibroblast growth factor 1 (FGF1) to restore blood sugar control to diabetic animals for long periods of time. Their studies appeared in the Sept. 7, 2020, online issues of Nature Communications and Nature Metabolism.

A skirmish is shaping up between Jazz Pharmaceuticals plc and Avadel Pharmaceuticals plc in sleep disorders. Investors clipped shares of Avadel recently as anxieties rose over the application by Jazz Pharmaceuticals plc for a patent that relates to a once-nightly oxybate product that could threaten the prospects for Avadels FT-218. Dublin-based Jazz gained approval this summer for Xywav (calcium, magnesium, potassium, and sodium oxybates) for cataplexy and excessive daytime sleepiness (EDS) in patients ages 7 and older with narcolepsy.

The volume of clinical data reported throughout the summer has continued to fall, with only 267 items collected in August, a drop of 10% from July and the lowest amount within the last five months. With hundreds of clinical trials negatively affected in prior months by the COVID-19 pandemic, the reduction in reportable events is not surprising. Still, 15% of the Phase I, II and III clinical briefs entered into the BioWorld database during August were focused on vaccines and therapeutics for COVID-19.

Click Therapeutics and Boehringer Ingelheim GmbH inked a deal valued at more than $500 million to collaborate on the development and commercialization of a prescription-based digital therapeutic for schizophrenia. The mobile application, currently called CT-155, uses cognitive and neurobehavioral techniques to reduce the negative symptoms of schizophrenia such as cognitive deficits and impaired social functioning.

HONG KONG The use of artificial intelligence in drug discovery was back in the spotlight on the last day of the 2020 KoNECT-MOHW-MFDS International Conference, with drug developers pointing out the challenges and possible solutions.

Appili, Atara, Aura, Bicycle, Biocomo, Biogen, C4, Cancer Prevention, Celltrion, Clearside Biomedical, Clene Nanomedicine, Editas Medicine, Eli Lilly, Galapagos, Greenwich Biosciences, Harbour Biomed, Hualan Genetic, ICER, Immunic, Immupharma, Intra-Cellular, Janssen, Junshi, Lavvan, LFB, Lyra, Medicinova, Partner, Prothena, Roche, Santhera, Seres, Sol-Gel Technologies, Spero, VBL

The rest is here:
Trillium follows positive data and a $25M equity investment with a $130M offering - BioWorld Online

Read the Rest...

Outlook on the Nanotechnology for Healthcare Market to 2025 by Application, E – News by aeresearch

§ September 12th, 2020 § Filed under Nano Medicine Comments Off on Outlook on the Nanotechnology for Healthcare Market to 2025 by Application, E – News by aeresearch

The global Nanotechnology for Healthcare Industry Report provides an in-depth and professional study on the current state of the Nanotechnology for Healthcare global industry. The research report further categorizes the global Nanotechnology for Healthcare market by key regions, top players and market segments. It bifurcates the global Nanotechnology for Healthcare market Size into different geographic segments to show organic growth across the globe including in the emerging economies.

The recent research report on Nanotechnology for Healthcare market offers a widespread assessment of market trends, as well as factors affecting the market expansion during the study period. It also incorporates details pertaining to market segmentations, and prominent manufacturers. The report also assesses the market drivers and opportunities. Also, the research report comprises of factors which may restrict the growth of Nanotechnology for Healthcare market over the analysis timeframe.

Additionally, the report provides notable inputs based on the impact of COVID-19 on the market scenario.

Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/298137

A gist of the regional analysis of the Nanotechnology for Healthcare market:

North America, Europe, Asia-Pacific, South America, Middle East & Africa are the segments of Nanotechnology for Healthcare market based on the regional analysis.

Other features of the Nanotechnology for Healthcare market report:

What are the market factors that are explained in the report?

Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/298137

See the article here:
Outlook on the Nanotechnology for Healthcare Market to 2025 by Application, E - News by aeresearch

Read the Rest...

The Planetary Biome: A New Theory of Life and Survival – SFGate

§ September 8th, 2020 § Filed under Nano Medicine Comments Off on The Planetary Biome: A New Theory of Life and Survival – SFGate

By Deepak Chopra MD and Rudolph E. Tanzi, PhD

The global pandemic has disrupted everything we call normal life. The disruption has been so catastrophic that there is fear among experts that this is only a starter pandemic. COVID is less infectious than the measles and less fatal than SARS. Instead of using this fact to stoke fear, we can do a great deal to heed COVIDs wakeup call.

A new way of looking at life itself holds out hope and optimism, because the popular image of deadly viruses assaulting humans like microscopic aliens is incorrect. Microbes are the very basis of life. We interact with them constantly, and much more than 99% of the time life is enhanced. Every advanced life form, including us, has microbial DNA woven into its own genome. A vast colony of bacteria known as the microbiome together with viruses (the virome) and fungi (the mycobiome) that inhabit every animals digestive tract, and when it comes to mammals, the microbiome not only makes digestion possible, but it connects us to the planetary biomethe totality of viruses, bacteria, and fungi that truly rules the earth.

It is a very benign rule. Look around at the astonishing diversity of life that evolution has produced. Evolution in higher life forms is the visible outcome of activity in the planetary biome. To keep the creation of new life beneficial, as it has been for billions of years, the first lesson of the new model is to realize that we are life itself. Our actions affect Nature directly in ways that either enhance life or lead it into destructive patterns.

If we look at COVID as a response, or even a message from the planetary biome, what is the message about? It is about disruption and imbalance. The microbial world responds quickly, at times instantly, to aberrant conditions. Fortunately, it can also respond quickly to rebalance itself, since balance is the natural tendency of every level of life.

Human beings are responsible for imbalance and disruption in many ways, most of them the product of modern life. We can begin with viruses. The earth has a global virome, which is currently being mapped at Stanford. This Earth database, once completed, which also allow us to identity the viruses in the human virome.

As in the human virome (and the microbiome and mycobiome), there can be dysbiosis, when one microbe goes out of balance and becomes opportunistic, amplifying itself at the expense of others. On a larger scale, humans, among all mammalian species, are being opportunistic as we remove forests and wetlands and pollute the land and oceans, leading to an unprecedented rate of extinction of species.

The novel COVID virus was most likely introduced into humans from other mammals as we insist on eating food from species that are too close to our genetic makeup (a notorious example being Chinas so-called wet markets). By design in our evolution, the human microbiome prefers plants (our teeth, stomach acid, colon structure, and our need for plant fiber to feed our gut microbiome all support this conclusion).

The consumption of animals, especially mammalian species that are genetically more similar to humans, leads to putrefaction and microbial dysbiosis. As we make ourselves sick, we also propagate the production of opportunistic bacteria that disrupt the earths microbiome. Through the same meat diet we also propagate viruses and fungi that disrupt the earths virome and mycobiome. Our disruption extends to inducing and accelerating new mutations across all species on Earth with increasing levels of pollution at the chemical, electromagnetic, and radioactive levels.

As essential as electricity is to modern life, our pollution-generating activities accelerate mutation in ourselves as well as in life forms below us. We, and the planet as a whole, are healthiest when we create maximal evolutionary and genetic distance in our food chains. Genetic distancing is now needed more than ever. Otherwise, our many activities that pollute the earth first accelerate the introduction of new mutations in viruses and bacteria in ourselves and in other mammals (we arent the only species susceptible to COVID, for example). Then we eat these other mammals and disrupt our own microbiomes with new infections, some of which are potentially fatal.

The message from the pandemic wont be received immediately or completely understood and accepted. But hope arises because the planetary biome is the true foundation of life and the ecology that entangles all living things. Humans are the pivot point, now and in the future. We are the mirror of the earth and of life itself. A conscious alliance with the evolutionary gifts of the biome opens the way for a future free of pandemics and many disorders that can be treated from the microbial level on up to cells, tissues, and the whole person. The potential in medicine alone is enormous. What we need to do now is to take this new model seriously and to learn how best of live as part of the planetary biome.

DEEPAK CHOPRA MD, FACP, founder of The Chopra Foundation, , a non-profit entity for research on well-being and humanitarianism, and Chopra Global, a modern-day whole health company at the intersection of science and spirituality, is a world-renowned pioneer in integrative medicine and personal transformation. Chopra is a Clinical Professor of Family Medicine and Public Health at the University of California, San Diego and serves as a senior scientist with Gallup Organization. He is the author of over 90 books translated into over forty-three languages, including numerous New York Times bestsellers. His 90th book, Metahuman: Unleashing Your Infinite Potential, unlocks the secrets to moving beyond our present limitations to access a field of infinite possibilities. For the last thirty years, Chopra has been at the forefront of the meditation revolution and his next book, Total Meditation (Harmony Book, September 22, 2020) will help to achieve new dimensions of stress-free living and joyful living. TIME magazine has described Dr. Chopra as one of the top 100 heroes and icons of the century. http://www.deepakchopra.com

Dr. Rudolph E. Tanzi is the Kennedy Professor of Neurology at Harvard Medical School and Vice-Chair of Neurology and Co-Director of the McCance Center for Brain Health at Massachusetts General Hospital. Dr. Tanzi has discovered numerous Alzheimers disease genes, including the first one, and is developing new Alzheimers therapies using human mini-brains pioneered in his laboratory. Dr. Tanzi has published 600 research papers, received numerous awards and was on the 2015 TIME100 Most Influential People in the World list. He has also co-authored several books, including Decoding Darkness and three bestsellers with Deepak Chopra: Super Brain, Super Genes, and The Healing Self. In his spare time, he plays keyboards with guitarist, Joe Perry of Aerosmith and other musicians.

Read more:
The Planetary Biome: A New Theory of Life and Survival - SFGate

Read the Rest...

Is It Time To Revisit The Central Vac? – Forbes

§ September 8th, 2020 § Filed under Nano Medicine Comments Off on Is It Time To Revisit The Central Vac? – Forbes

The affects of indoor air quality are top of mind as we spend more time at home

Is your vacuum spewing particles back into the air?

The EPA cites indoor air quality (IAQ) as one of the top five environmental risks to public health. Since the pandemics March shut down, many people have been inside nearly 24/7. Our homes have been doing quadruple duty as office, restaurant, theater, school. We got a reprieve during the spring and summer when we could at least do a lot of things outdoors, but colder weather and shorter days are not far away and well be back inside once again.

While youre trying to keep your space clean and free of germs, youre likely doing lot of vacuuming. And recent research from University of California, Davis and the Icahn School of Medicine at Mt. Sinai, shows that while we typically imagine influenza viruses spreading via respiratory particles, they can also spread through the air on dust, fibers and other microscopic particles.

Are you doing more harm than good by vacuuming?

When you vacuum, you suck up dirt and fine particles into a canister. And, while your vacuum does have a filter, if its an old vacuum, its likely not doing enough to contain the tiniest particles, which will then just blow back into your home. If you or your family members are prone to allergies, this is a problem.

Harvards Healthy Building Program suggests that you vacuum regularly but use a vacuum with a HEPA (High Efficiency Particulate Air) filter. These filters, according to the EPA, can theoretically remove at least 99.97% of dust, pollen, mold, bacteria, and any airborne particles with a size of 0.3 microns.

Yet, even with a HEPA filter, if the vacuum is not sealed well or the filter is faulty, jostling the vacuum is enough to release particles into the air. (To see this explained check out this video from Vacuum Wars, a vacuum cleaner review and comparison channel.) So if you buy a portable vacuum, invest in one that has a HEPA filter with a sealed system. And, when you empty the canister, dont do it in the house.

With some systems you can get a baseboard sweep inlet to suck up crumbs.

If only there were a vacuum system that you didnt have to schlep from room to room, that sends dirt and particles directly to a separate canister and that only has to be emptied a couple of times a year. Oh, wait, there is, and its been around since the 1950s.

The central vacuum is one of those great inventions that has had trouble catching on. A typical central vacuum system has about a six-gallon collection bucket located in a garage, crawl space or attic; ductwork in the walls; connection points or inlets in several rooms (a 2,400-square foot home only needs four inlets) and a 35-foot hose (it can be retractable) that you connect to the inlet.

So why isnt central vac as mainstream as central A/C and other built-in appliances and mechanicals? It may come down to price. A central vacuum runs anywhere from $1,000 to $2,000 installed (add about $500 if its a retrofit). Thats a tough sell when you can buy a good vacuum for under $200.

Sean Finnerty and his father Dennis Finnerty co-founders of HausVac are trying to change perceptions of central vacuum systems by, among other things, offering courses to architects and design professionals. Based in the Hamptons on the east end of Long Island, HausVac manufactures and installs its own central vacuum components. The companys niche may be luxury builds, but Dennis says that about 10% of homes in the U.S. are equipped with central vacuum systems and that its easy enough to install a central vacuum in an existing home. In fact, according to Green Builder, one-third of all central vacuums sold in the U.S. are installed in existing homes without tearing out sections of walls or ceilings.

People have seen it as a niche item, says Dennis but its a vital health imperative particularly now with concerns about viruses and a renewed focus on indoor air and health.

Read this article:
Is It Time To Revisit The Central Vac? - Forbes

Read the Rest...

Kitty stool can help ID diseases – The Tribune | The Tribune – Ironton Tribune

§ September 8th, 2020 § Filed under Nano Medicine Comments Off on Kitty stool can help ID diseases – The Tribune | The Tribune – Ironton Tribune

Stinky butt!

I think the starter of the childhood taunt must have been around kittens.

Fall brings an abundance of kittens. Because of the increase in kittens, we have seen a rash of kittens with diarrhea lately. Note: diarrhea is a symptom, not a disease. You dont catch diarrhea. You catch something that causes diarrhea.

Diarrhea can be caused by the small intestines or in the colon. The type of diarrhea has clues to the cause.

This is so important that we recently had a twenty-minute staff meeting discussing how to characterize diarrhea.

Diarrhea needs several descriptors to be adequately categorized. Is it frequent? Is there an urgency?

Does it run out, leak out or is it projectile? Is it black, brown, green, red, bloody or yellow? Does it have mucous or fresh blood? Is it watery, pasty, chunky or thick? Is part of it normal and then more lose as it comes out?

What does it smell like? Can you smell it from over there or just up close? Is there vomiting or other sickness with the diarrhea?

Kitten diarrhea is often caused by simple things like diet.

Kittens are lactose intolerant, so cows milk is a great way to cause diarrhea. This is usually self-limiting.

Some foods are not balanced and can cause diarrhea. Diet is not only too much of something, it can be an allergy.

A bacterial cause of diarrhea, Salmonella, can be transferred in raw food diets. Actually, Salmonella is quite common in the raw diets and can be fatal.

Another form of bacterial diarrhea is campylobacter. It is transferred with contaminated soil or food and can be fatal.

Bleu Skye probably has a bacterial diarrhea. Her white blood cell count is high and she has a concurrent pneumonia. She is spending a few days in the respiratory isolation ward of the hospital on injectable antibiotics.

I picked up a bacterial diarrhea from my time volunteering with sled dogs in Alaska. The temperatures were too cold to have adequate sanitation and a mainstay of a sled dog diet is raw foods. Somehow some of the human food became contaminated and I was very sick. Within two hours of my MD prescribing the appropriate antibiotic, I started to feel better. I wish I hadnt waited a week to get in to see him.

Parasites are common in kittens and can cause diarrhea. Hookworms and roundworms are present at birth or in the mothers milk while the kittens are nursing.

Hookworms are tiny (virtually microscopic) worms. They cause a problem because they dont come in dozens or hundreds, but in thousands or more.

Each hookworm bites a place on the inside of the intestine. The hookworm then secretes an anticoagulant to keep the blood flowing. After a while, it doesnt flow fast enough and the hookworm will move and bite a new spot to lap up blood.

Each of the thousands of worms can have up to six spots bleeding at any one time.

Roundworms are the larger pasta like worms that can fill up the intestines with their numbers. Either way, the damaged intestines cannot process well and the kitten has diarrhea. This is so common, that we automatically treat all kittens (and puppies) for this when we see them.

Kittens can have protozoal diarrhea also. Protozoa are microscopic, one-celled organisms that can be free-living or parasitic in nature. They are usually transmitted by dirty drinking water. Amebiasis is usually a large intestine infection, but it can affect the liver and pancreas. Coccidia can be self-limiting in cats, but can hit kittens fairly hard.

The yellow pasty diarrhea may be a coccidia, but a stool sample microscopic exam will help your vet diagnosis it. Giardia and other like protozoa affects the small intestine. It is hard to diagnose and can be difficult to treat and/or clear up.

We are currently treating a litter of six kittens. While all of them have a protozoal diarrhea, only one is really sick. Luckily, his new mom (who found them abandoned) is caring for him and getting his medicine in him.

Stella is an adorable Blue Russian who is also in the hospital in the gastrointestinal isolation room.

Stella probably has a viral diarrhea. Viral diarrhea in kittens can be frustrating. Often the poop just leaks out. They walk, it leaks. They sleep, it leaks. And it waxes and wanes, meaning it gets better and then it is back to square one.

The most common viruses that cause kitten diarrhea are pan leukopenia (a parvo virus), feline immunodeficiency virus (FIV), feline leukemia (FeLV) and rotavirus.

We tested Stella for the first three of these viruses and she was negative. Unfortunately, a negative test is not that accurate. If they are positive, that is highly accurate, but just as we are seeing with

COVID-19, a negative test doesnt mean that you are really negative.

Meanwhile Stella has tested negative for the other types of diarrheas or did not respond to those treatments. Viral diarrhea is common enough that I saw six cases during an ER shift last weekend.

That means it is reasonable to assume that she had a viral diarrhea.

Although there is not a specific treatment, most kittens recover from viral diarrheas, if you keep them alive long enough. That means we are giving supportive care in the means of fluids and highly digestible foods.

In the past two weeks I have seen about a dozen cases of kitten diarrhea. All of them had their own reasons for diarrhea, but they all had stinky butts and litter boxes!

MJ Wixsom, DVM MS is a best-selling Amazon author who practices at Guardian Animal Medical Center in Flatwoods, Ky. GuardianAnimal.com 606-928-6566

Here is the original post:
Kitty stool can help ID diseases - The Tribune | The Tribune - Ironton Tribune

Read the Rest...

The great beauty reset: how to reboot your skin – Financial Times

§ September 8th, 2020 § Filed under Nano Medicine Comments Off on The great beauty reset: how to reboot your skin – Financial Times

Im not saying my skin has aged significantly this year but my six-year-old recently asked me why I had asix-pack on my forehead. After six months of stressful days, sleepless nights and home-school nightmares, its become apparent that matters need taking in hand. And theres something about the early autumn, with its nip in the air, and its new-found appreciation for proper, non-negotiable routines that feels right for a skincare overhaul.

Fortunately, the seasons big skincare launches abound with new ways to reset your skin, from serious, sleeves-rolled-up jump-starting regimens, which last up to a month and deliver a rapid burst of intense reconditioning, to new strategies that claim todetoxify your daily regime without your having to somuch as cut down on caffeine.

Sorting out most modern-day skincare complaints from sluggish cell turnover caused by tiredness and stress to overstimulated skin (a result of using products not suited to one another), to undeserved lacklustre complexions caused by outdated products requires a bit of areboot. It could be a facial; it could be a peel. But inthedays when weve all become beauty hobbyists, performing DIY facials like pros, it could also be a pleasurable at-home experience for the price of a couple ofdecent salon treatments.

Dr Anita Sturnham, a London-based GP specialising in dermatology who launched her own excellent skincare line,Decree, last year, became so aware of how many of herpatients especially those suffering with breakouts, pigmentation and dehydration needed a thorough overhaul that she recently launched her own two-week Skin Reset Kit. Sturnham believes 90 per cent of the skin issues she sees are self-inflicted simply by using the wrong products and that stripping your skincare right back is an essential step for getting the best from your skin.

Another recent reset kit is Budapest brand Omoroviczas The Cure programme, which in nine days cycles through anacid phase (to resurface), a remineralise phase (tostimulate microcirculation) and a reconstruct phase (forrenewed elasticity). You can repeat it every three months, ideally to coincide with the change of seasons.

One of the best known brands for an intensive treatment is that of anthropologist-turned-dermatologist Dr Phillip Levy. A Geneva-based wound-healing specialist,he believes that only via resetting can you achieve some of the most visible anti-ageing results andhis Ultimate Stem Cell Spring Homecure (the springmeans spring clean but it can bestarted any time)is legendary. Manyofthe cures we have studied over the years seem to be everyday products nicely repackaged, he says.But to have something truly transformational, theyneed go deep enough to stimulate your own collagen, elastin and hyaluronic acid production, and last four weeks or even eight or more.

Its true that these regimes work best when they feel elevated from the everyday. And when it comes to products with a built-in sense of occasion, no one does it better than Sisley. Even before you get to the science and the scents, and the textures it has a particular French earnestness that makes every product feel like an event. Which must make LIntgral Anti-Age La Cure, its new skin-resetting regimen, at 775 for a four-week supply, a veritable tapis rouge.

For each of the four week-long phases Impulse, Reset, Consolidate, Renaissance theres a phial of creamy serum, about the size of an eye cream. You use each one for seven days, applying eight pumps of product morning and night (this feels a lot, and it takes a few minutes to properly sink in). You can follow with eye cream or moisturiser if you want to, but I didnt feel the need. The bottles have been slightly overfilled so as to ensure you dont run out, but when you get to the end of the seventh day, you must start the next one nonetheless. (This feels wasteful, but I was assured by Sisleys training manager Lorna Green that I could save up these last drops and use them a couple of weeks after the course, as a further boost).

The formulation works on the skins mitochondria the batteries where cellular energy is stored. Theylose the ability to restore themselves over time, particularly during intense periods of stress and hormonal changes, so following either one of those would be an ideal time to try it. The breakthrough wasthe discovery of the mechanisms of a process called autophagy (for which Japanese biologist Yoshinori Ohsumi won the Nobel Prize for medicine in2016), whereby damaged cell components such as mitochondria destroy themselves to protect the rest ofthe cell. La Cure boosts the elimination of these wasteelements, allowing the healthy cells left behind tosoak up energy and regenerate promoting the appearanceof healthier, more youthful skin. In skincare terms, this is no mean feat.

Where the real technology is happening, it wont be long before they eclipse the big jars of moisturiser completely

It sounds intense and its certainly super-active: by the end of the first week I had a small, yet determined, spot on my chin (which I cannot believe was a coincidence) and a little more redness than usual, too. The following week, cell detoxification week, my skin was starting to feel unusually smooth. By the end of the fourth week, my skin was smoother and clearer than I can ever remember. Its also, though, a real example of skincare as self-care: as much as the thought of a radically rejuvenated complexion, the daily reminder that youve sidelined your usual clutter of products in favour of something exceptional is almost enough to bring on a glow.

With any reset complete, the focus should then be on keeping your skin detoxified and renewed. One update worth looking at is a serum. Whereas the luxurious facecream at the end of your regime used to be the jewel in any skincare crown, these dayslightweight serums are where the real technology ishappening, and it wont be long before they eclipse thebig jars of moisturiser completely.

While serums used to be a targeted addition to your face cream specifically for age spots, say, or wrinkles the best new ones are genuinely impressive all-rounders. Este Lauder has just revamped Advanced Night Repair, one of the first ever mainstream skin serums and a product so ubiquitous that among beauty editors it has acronym status. (See also: Cliniques DDML, aka Dramatically Different Moisturizing Lotion). And in October, Suqqu, which hails from Japan where serums have been the mainstay of skincare much longer than here will launch Vialume, its most advanced line yet, containing glucosamine and amino-acid derivatives designed to targetall five key characteristics of great skin: moisture, firmness, smoothness, translucency and brightness.

Another product gaining increasingly scientific status is face oil, which should no longer be dismissed as the preserve of the militantly natural beauty brigade. Augustinus Bader, the world-leading wound-healing specialist whose Rich Cream was the runaway skincare success of 2018, has just launched The Face Oil, which contains a slew of delicious-sounding oils argan, babassu, hazelnut, karanja as wellas a healthy dose of TFC8, the complex of vitamins, amino acids and synthesised molecules that has made Baders products famous. Meanwhile, RVive Glow Elixir Hydrating Radiance Oil is bronze in colour and slightly shimmering although unusually, it leaves no evidence of glittery particles. Alongside a cocktail of seed oils, it contains the brands signature Bio-Renewal Protein, rendering it a real skincare/make-up hybrid and a great transitional product for this time of year.

Another need-to-know and a great option particularly for younger skin is Rihannas new Fenty Skin line. Theres Total Cleansr, which would work especially well as the first step of a double-cleanse, and Fat Water, which Ri-Ri calls a toner-serum hybrid but its the Hydra Vizor daily moisturiser that triumphs. This so-called Invisible Moisturizer has an SPF30 that leaves no white cast to the skin whatsoever, primarily because the product has a gorgeous pinkish hue and a blurring effect. The ghostly pallor left behind by so many SPF products is a particular challenge to people of colour and this range was designed to work seamlessly with make-up on all skin tones. It also smells great juicy with just the slightest medicinal tinge and comes in a refillable tube.

The recently launched skincare brand U Beauty wants to reset not just your skin, but the way you think about your whole regime. Were all doing too much, says founder Tina Craig, who until two years ago was working as an influencer/ambassador for the worlds biggest skincare brands but admits being as confused as anyone about what to use; she had ended up with a 13-step skincare routine. I started noticing that everyone Iknew had skin that looked translucent, which is not how it should look, she says. Then I looked at my grandma and relatives in Korea, and their skin was not like that. It was thick. Dense. Firm.

U Beauty is her answer to what she calls the cosmeticconfusion. Its first product, the Resurfacing Compound (which sold out three times on UK stockist Net-aPorter), was designed to replace toner, vitamin C, hyaluronicacid, AHAs, physical exfoliants, antioxidant serums and retinol products. From this month, theres alsoSuper Smart Hydrator, a moisturising serum that seeks out damaged cells and only treats the skin where itneeds it. Bookend these two with cleanser and SPF, saysCraig, and youre good to go.

Finally, could we reset the way we use products altogether? New US brand Noble Panacea is overseenby ascientific heavyweight: Sir Fraser Stoddart, who was awarded the 2016 Nobel Prize in chemistry. A microscopic delivery system releases its active ingredients into the skinin a programmed sequence, and it comes in individualdoses packed in mini sachets to ensure the optimal amount of these ingredients stays potent until theminute it reaches your skin.

On the one hand, they feel counter to the idea of luxury face creams more like a free sample from a beauty hall but on the other, the boxes made from renewable materials and ultra-hygienic 0.5ml doses feel modern and Covid-safe. (You can send them for recyling in a complimentary envelope to TerraCycle, with which the brand has partnered). And if nothing else, as its global ambassador ithas snapped up the actress Jodie Comer, who must havebeen pursued by every beauty company under the sun and as far as I can tell, theres no sign of a six-pack on her forehead.

Excerpt from:
The great beauty reset: how to reboot your skin - Financial Times

Read the Rest...

Great ExpectationsDevoted Health and the positive patient experience – MedCity News

§ September 8th, 2020 § Filed under Nano Medicine Comments Off on Great ExpectationsDevoted Health and the positive patient experience – MedCity News

Heres a potentially big idea, friends! In order for practitioners to focus on great patient experiences, payers/payors (the insurance companies) need to incent the delivery of great patient experiences. In this article we take a look at Devoted Health, a payvidor that focuses on delighting patients when they need it most. Brothers Todd and Ed Park founded the Waltham, Massachusetts-based combo healthcare payer and provider in 2017 with the driving principle that love matters . . . that a culture of love for each other and for patients is important to sustainably providing the best care possible.

A MedCity News journalist wrote last year, When asked about the main differentiation between Devoted and some of the other insurance startups, the Parks had a simple, if somewhat trite, answer: love.

Because love is a loaded term to use in the workplace, its worth stating that they focus on establishing familialtype (not romantic) love. Thearticle quoted co-founder Todd Park as saying, The standing order for the whole company is when doing any action or making any decision close your eyes, imagine the face of someone in your family you love desperately and ask yourself if you were making the decision to impact him or her directly, what would you do?

Devoted aims to build a health care plan that treats every member like they are family; its logo is a heart. Compare this mission to a few organizations we selected that are roughly comparable:

Kaiser Permanente believes it exists to provide high-quality, affordable health care services and to improve the health of their members and the communities they serve.

Clover Health says its mission is to align with physicians by reducing doctor-insurer friction and increasing visibility into the health of each patient, leading to improved care.

EmblemHealths statedmission is to create healthier futures for its customers and communities.

The point is that unlike the three comparison points, Devoted has a focused, human mission rooted in empathy.

As far as execution, we see three key ways Devoted is achieving its goal of love for patients. However, before we delve into those three operational strengths, we want to make sure this article isnt misconstrued as a puff piece for Devoted. Were not investors in Devoted, and with this moonlighting gig where we write articles about patient experience, we arent in the business of serving as the marketing arm for companies. We co-author articles as our version of healthcare writing-and-change-agency. We are hugely committed to the idea that organizations must improve delivery of the patient experience. Despite being impressed with the Devoted strengths, we want to state that Devoted is today an unprofitable experiment. Being dependent on investment capital for its survival, it hasnt proven that its hypothesized points of strength will work as a long-term, sustainable company that generates profits.

Okay: back to our regular programming . . . the specifics of how Devoted is able to improve the patient experience where others cant and dont.

Original post:
Great ExpectationsDevoted Health and the positive patient experience - MedCity News

Read the Rest...

« Older Entries Newer Entries »



Page 21234..1020..»